Anavex Life Sciences has announced promising data from its 48-week open-label extension study,
highlighting the potential of their lead drug candidate, ANAVEX®2-73
(blarcamesine), in treating Parkinson’s disease dementia. The study
demonstrated that ANAVEX®2-73 showed significant clinical benefits, achieving
both primary and secondary objectives over the trial period.
ANAVEX®2-73 is an oral small-molecule activator of the sigma-1 receptor, which plays a crucial
role in restoring neural cell homeostasis and promoting neuroplasticity. Anavex’s innovative approach offers a novel potential treatment for
neurodegenerative diseases, including Parkinson’s disease, which affects over
10 million people worldwide.
The study assessed various parameters, including the Movement Disorder Society-Unified Parkinson’s
Disease Rating Scale (MDS-UPDRS), Clinical Global Impression – Improvement
(CGI-I), and Montreal Cognitive Assessment (MoCA). Results indicated consistent
improvements in patients’ clinical symptoms over the 48 weeks under ANAVEX®2-73 treatment.
Dr. Christopher U Missling, President & CEO of Anavex Life Sciences, expressed optimism about
the outcomes. He noted, “The consistent improvement in clinical symptoms over
time is encouraging and suggests ANAVEX®2-73’s potential to address the urgent
unmet global need in Parkinson’s disease treatment.”
Anavex Life Sciences plans to leverage these promising results to advance to a
pivotal trial for ANAVEX®2-73 in Parkinson’s disease, furthering their
commitment to developing therapeutics for neurodegenerative and
neurodevelopmental disorders. The company, headquartered in New York, focuses on
a range of CNS disorders, including Alzheimer’s disease and Rett syndrome,
showcasing a robust pipeline of innovative treatments.
The positive data from this extension study underscores ANAVEX®2-73’s therapeutic potential and
strengthens Anavex’s position in the biopharmaceutical industry. As the company
moves forward, these findings could mark a significant step towards more effective
treatments for Parkinson’s disease and other CNS disorders.
Read this article for more information.
Learn more about Anavex on https://finance.yahoo.com/quote/AVXL/